SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-013989
Filing Date
2021-11-02
Accepted
2021-11-02 07:32:04
Documents
76
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20210930x10q.htm   iXBRL 10-Q 2034271
2 EX-31.1 acrs-20210930xex31d1.htm EX-31.1 15682
3 EX-31.2 acrs-20210930xex31d2.htm EX-31.2 15688
4 EX-32.1 acrs-20210930xex32d1.htm EX-32.1 9520
  Complete submission text file 0001558370-21-013989.txt   8149743

Data Files

Seq Description Document Type Size
5 EX-101.SCH acrs-20210930.xsd EX-101.SCH 48498
6 EX-101.CAL acrs-20210930_cal.xml EX-101.CAL 53015
7 EX-101.DEF acrs-20210930_def.xml EX-101.DEF 171119
8 EX-101.LAB acrs-20210930_lab.xml EX-101.LAB 514366
9 EX-101.PRE acrs-20210930_pre.xml EX-101.PRE 346276
10 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20210930x10q_htm.xml XML 1615010
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 211369270
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences